Member Info for AVCT

"...This is important because the next fund raise will be determined by the data from P1b."

Glad to see you confirming that you think the next fundraise won't be until H2 at the earliest.

@WAG

Its just not news which hasn't already been given by the company in announcements or presentations- for those who can read and listen

No - its no big loss of information

What information is undisclosed?

It's just a bit sad really that CC thinks the TG group members are so thick she has to explain to them the (not so well) " hidden messages" and explain the meaning of imminent

So by your own words Whinny you're a punter like the rest of us who sees worthwile possibility for upside rather than an investor

If you don't see any worthwhile potential upside then you're either bonkers or should sell your imaginary shares, or ideally open an imaginary short. Then you'd be taken seriously and people can judge to follow your view or dismiss you as the deramper you are, if they wish.

Ps don't expect a response to whatever drivel you post in response to this

Cutting to the key phrase from CC

"We will not strike a deal for the sake of striking a deal, where we don’t feel we are getting the right validation or the funding the technology really...."

My understanding was that Tempus made money by selling their data

For me we are a client of Tempus - never really understood the partnership reference

You repeat the original generic bumph like an AI bot which appears to not understand the question

Meant to say - actual calculations for

Would love to see the "adjusted financial performance, "

Thanks in advance

Would love to see where these

"active options contracts currently traded on UK derivatives exchanges"

Are

Would love to see the "adjusted financial performance, "

Thanks in advance

Potential competition as all PDC/ADC are

But different method of action - doesn't cleave externally to cancer cell

"...uses a pH-low insertion peptide (pHLIP) to selectively deliver its payload into the cytoplasm of cancer cells."

You're a deramper

Occams razer and all that

Toodle pip

Ps

If it's INCOCEIVABLE - by definition you shouldn't be investing Wyn

Although I doubt whether you actually are

DYOR

"....because if the data to sate was as good as we are led to believe it is inconcievable that the SP would be falling through every part of the trial updates."

This is not true as share price and potential future value are driven by completely different largely un- connected factors

The need to raise capital and elongating timelines have a more immediate effect on share price than on potential future value ( which also has a discounted current value )

While improving future potential value have little effect on current share price

Just the way it is until it isn't

"And it shows the markets are heavily weighted on revenues not product potential."

It is until it isn't and therein lies the opportunity if you can see it

For "Avacta are being too greedy or incompetent to negotiate a deal" read sticking to their guns on the true value of our IP - imo

For "diluted to fook" replace with listed on Nasdaq - imo

"...what we’ve witnessed with avacta, interim results in all phases of trials happen."

P1a was a series of sequential increasing dose cohorts - which lend themselvesv to interim updates

Is P1b not going to be a rolling enrolment at a single dose completing sometime mid year?

An interim update after completion yes and "full" results at end of year before start of P2

Anything earlier publicly, not so sure myself - those negotiating deals who need to know probably will

imo

"Alternatively, they might secure a smaller deal for AVA6000 to help fund Phase 2 progression"

As I said brokered off the back of P1b imo